|
Market Closed -
Nasdaq
16:00:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 11.18 USD | -1.93% |
|
+1.18% | -45.09% |
| 09-29 | Keros Therapeutics Expects $20 Million Milestone Payment From Takeda | MT |
| 09-29 | Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda | CI |
Company Valuation: Keros Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,369 | 1,323 | 1,191 | 641.2 | 620.3 | 221.7 | - | - |
| Change | - | -3.39% | -9.94% | -46.17% | -3.27% | -64.26% | - | - |
| Enterprise Value (EV) | 1,369 | 1,323 | 860 | 81.3 | 620.3 | 221.7 | 221.7 | 221.7 |
| Change | - | -3.39% | -34.98% | -90.55% | 662.95% | -64.26% | 0% | 0% |
| P/E | -23.2x | -11.6x | -7.65x | -3.17x | 8.85x | -2.02x | -1.79x | -2.4x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.82x | -0x | 0x | -0.1x | 0.1x |
| Capitalization / Revenue | 68.1x | - | 7,889x | 181x | 2.54x | 14.2x | 16.1x | 4.96x |
| EV / Revenue | 0x | - | 0.01x | 0x | 0x | 14.2x | 16.1x | 4.96x |
| EV / EBITDA | - | - | -0x | -0x | 0x | -2.01x | -2.54x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -1.84x | -1.44x | -1.61x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -2.23x | -1.77x | -1.88x |
| FCF Yield | -4.61% | -5.39% | -10.7% | -25.3% | 17.1% | -44.8% | -56.6% | -53.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.52 | -4.15 | -5.2 | -5 | 2.3 | -5.537 | -6.236 | -4.657 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 20.1 | - | 0.151 | 3.55 | 244.1 | 15.57 | 13.73 | 44.69 |
| EBITDA 1 | - | - | -169.1 | -209.6 | 69.08 | -110.4 | -87.15 | - |
| EBIT 1 | -56.37 | -114.8 | -169.9 | -210.8 | 67.57 | -120.5 | -154.3 | -137.9 |
| Net income 1 | -58.74 | -104.7 | -153 | -187.4 | 87.01 | -110.4 | -147.4 | -133 |
| Net Debt | - | - | -331.1 | -559.9 | - | - | - | - |
| Reference price 2 | 58.51 | 48.02 | 39.76 | 15.83 | 20.36 | 11.18 | 11.18 | 11.18 |
| Nbr of stocks (in thousands) | 23,399 | 27,543 | 29,959 | 40,507 | 30,466 | 19,827 | - | - |
| Announcement Date | 3/9/22 | 3/3/23 | 2/28/24 | 2/26/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.06x | - | - | -.--% | 226M | |
| 19.21x | 6.83x | 13.69x | 1.55% | 66.34B | |
| 36.32x | 6.47x | 19.31x | 0.89% | 52.92B | |
| 29.51x | 8.11x | 25.65x | 0.05% | 54.82B | |
| 34.13x | 3.33x | 14.37x | -.--% | 44.09B | |
| 50.62x | 5.85x | 32.15x | -.--% | 43.72B | |
| -20.41x | 209.35x | -21.69x | -.--% | 42.13B | |
| 29.48x | 8.35x | 21.6x | 0.36% | 33.96B | |
| 30.25x | 6.41x | 16.63x | -.--% | 26.17B | |
| 31.94x | 5.89x | 19.81x | -.--% | 23.37B | |
| Average | 23.90x | 28.95x | 15.73x | 0.28% | 38.77B | |
| Weighted average by Cap. | 26.33x | 28.52x | 15.73x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- KROS Stock
- Valuation Keros Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
